Nanjing Pharmaceutical: Revenue in 2025 is 54.963 billion yuan, with a year-on-year increase in net profit of 9.50%.

Nanjing Pharmaceutical announced that by 2025, the company achieved operating income of 54.963 billion yuan, an increase of 2.36% year-on-year; total profit of 1.158 billion yuan, an increase of 15.37% year-on-year; and net profit of 625 million yuan, an increase of 9.50% year-on-year. The asset-liability ratio was 73.74%, a decrease of 0.87 percentage points year-on-year. The company focuses on innovation and transformation in its core business, with growth in retail, equipment and other businesses, advancing key logistics project construction and revitalizing existing assets. Additionally, the company strengthens technological innovation, improves corporate governance, introduces strategic investors, implements equity incentives, carries out share buybacks, and emphasizes investor returns and communication.